Related Experiment Video
Updated: Sep 6, 2025
07:55
Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
512
MicroRNA Networks in Cognition and Dementia
Grace S Blount1, Layton Coursey1, Jannet Kocerha1
1Department of Chemistry, Georgia Southern University, Statesboro, GA 30460, USA.
Cells
|June 24, 2022
Summary
Noncoding microRNAs are crucial epigenetic regulators, especially in the central nervous system. This review explores their role in dementia and neurodegenerative diseases, including viral impacts, and their therapeutic potential.
Area of Science:
- Genomics and Epigenetics
- Neuroscience and Neurology
- Molecular Biology and RNA Therapeutics
Background:
- Noncoding RNAs, once dismissed as 'junk' DNA, are now recognized as critical epigenetic regulators in human health and disease.
- MicroRNAs (miRNAs) play a significant role in the central nervous system, offering potential for diagnosing and treating neurological disorders.
- Neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's are characterized by cognitive decline, with limited treatment options.
Purpose of the Study:
- To review the pivotal role of microRNAs in the pathogenesis of major neurodegenerative and dementia-related disorders.
- To discuss microRNA-associated networks, including inflammatory and viral pathways (e.g., SARS-CoV-2), influencing these conditions.
- To examine the current status of microRNA-based clinical trials for neurological diseases.
Main Methods:
- Literature review and synthesis of existing research on noncoding RNAs, microRNAs, and neurodegenerative diseases.
- Analysis of microRNA networks implicated in cognitive decline and neuropathology.
- Examination of clinical trial data for miRNA-based therapeutics in neurological disorders.
Main Results:
- MicroRNAs are integral to the molecular mechanisms underlying various neurodegenerative conditions, including Alzheimer's, Parkinson's, and Huntington's disease.
- Inflammatory and viral infections (like COVID-19) significantly interact with miRNA pathways, exacerbating neurodegeneration.
- Emerging clinical trials show promise for miRNA-based diagnostics and therapeutics in treating dementia-related disorders.
Conclusions:
- MicroRNAs represent a paradigm shift in understanding and treating neurodegenerative diseases, moving beyond the 'junk DNA' concept.
- Targeting miRNA networks offers novel therapeutic strategies for conditions with currently unmet clinical needs.
- Further research and clinical trials are essential to fully harness the diagnostic and therapeutic potential of microRNAs in neurology.
Related Concept Videos
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
01:26Alzheimer's Disease: Overview
663
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260